Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study

Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study

Globally, dozens of COVID-19 vaccines are licensed under emergency or conditional authorization, but especially in low and middle-income countries, their availability varies. Indonesia decided to become independent and produce its own vaccines locally. This study investigated the safety and immunoge...

Full description

Saved in:
Bibliographic Details
Main Authors: Martira Maddeppungeng, Asrawati Nurdin, Yetty Movieta Nency, Rini Sekartini, Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, Muh. Nasrum Massi, Sidrah Darma, Andi Husni Esa Darussalam, Nur Ramadhani, Najdah Hidayah, Maisuri Tadjuddin Chalid, Sri Ramadany, Sitti Wahyuni, Irawaty Djaharuddin, Arif Santoso, Bahrul Fikri, Suriani Alimuddin, Ninny Meutia Pelupessy, Rina Masadah, Azka Zhafira Putri, Lilis Setyaningsih, Finny Fitry Yani, Fenty Anggrainy, Putri Awaliyah Deza, Nani Maharani, Endang Mahati, Rebriarina Hapsari, Nur Farhanah, Setyo Gundi Pramudo, Dimas Tri Anantyo
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Covid-19
immunogenicity
recombinant protein subunit vaccine
safety
SARS-CoV-2
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2429231
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2429231

Similar Items